Vitara Biomedical is a technology company.
Vitara Biomedical has raised $75.0M across 1 funding round.
Vitara Biomedical has raised $75.0M in total across 1 funding round.
Vitara Biomedical is a medical technology company developing EXTEND, a Neonatal Support Technology that creates a fluid-filled environment mimicking the womb to support extremely premature newborns for up to 28 days, delaying air exposure to allow organ development.[1][2] This addresses premature birth—the leading cause of death and disability in children under five—affecting 15 million babies annually worldwide, including 800,000 extremely premature cases, with nearly one million deaths and a U.S. economic burden exceeding $26 billion yearly; EXTEND could reduce mortality by 80% and long-term complications by 45%.[1] The company serves neonatal intensive care units (NICUs) and families of premature infants, headquartered in Philadelphia, Pennsylvania, with under 25 employees and total funding of $75 million across two rounds, including a recent $50 million raise.[2][3]
Founded in 2019 in Pennsylvania, Vitara Biomedical emerged to tackle the high risks faced by extremely premature infants through innovative therapeutic medical devices.[3][4] While specific founders are not detailed in available sources, the company's technology draws inspiration from Dr. Alan Flake, co-inventor and medical advisor, who describes it as potentially "life-changing" and a "new paradigm in pediatrics."[1] Early development focused on biologically inspired solutions modeled on fetal physiology, leading to pivotal funding traction with $75 million raised, signaling strong investor confidence in its womb-like support system for premature babies.[2]
Vitara Biomedical rides the trend of biomimetic medical devices in neonatal care, leveraging advances in fluid dynamics and fetal physiology to challenge decades-old incubator standards amid rising premature birth rates driven by maternal health factors and aging populations.[1] Timing aligns with growing investment in medtech for vulnerable populations—evidenced by its $75M funding—fueled by market forces like the $26B+ U.S. economic toll of prematurity and global demand for outcomes-focused innovations.[1][2] By potentially setting a new care paradigm, Vitara influences the ecosystem, inspiring similar womb-inspired tech and accelerating R&D in pediatric medtech startups.[1]
Vitara Biomedical is poised for clinical trials and regulatory milestones to commercialize EXTEND, building on its $75M war chest for scaling development and manufacturing.[2] Trends like AI-enhanced monitoring and personalized neonatal tech will amplify its impact, while partnerships with NICUs could drive adoption amid pressure for cost-saving, high-outcome solutions. Its influence may expand to shape global standards in prematurity care, transforming survival rates for the tiniest patients and echoing its mission: *Because Every Day Counts*.[1]
Vitara Biomedical has raised $75.0M in total across 1 funding round.
Vitara Biomedical's investors include 20VC, 9Yards Capital, Kevin Hartz, Addition, Afore Capital, Andreessen Horowitz, Buckley Ventures, Cedar Capital Group, Force Over Mass Capital, Index Ventures, Kaszek Ventures, Khosla Ventures.
Vitara Biomedical has raised $75.0M across 1 funding round. Most recently, it raised $75.0M Series B in September 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2022 | $75.0M Series B | 20VC, 9Yards Capital, Kevin Hartz, Addition, Afore Capital, Andreessen Horowitz, Buckley Ventures, Cedar Capital Group, Force Over Mass Capital, Index Ventures, Kaszek Ventures, Khosla Ventures, Latitud, monashees, NXTP Ventures, SciFi VC, Section 32, Biz Stone, Karim Atiyeh, Philippe Teixeira da Mota, William Hockey |